Amarin Corp Plc\Uk
AMRN Nasdaq Pharmaceutical Preparations Financials FY2016โFY2025
Last close ยท Oct 23, 2026
$11.79
1.6%What Amarin Corp Plc\Uk does
No business description yet.
- Legal name
- AMARIN CORP PLC\UK
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 2, 2026
- Accession ยท CIK
- 0001193125-26-085818
0000897448
Revenue and margins
Amarin Corp Plc\Uk had $214M of revenue in fiscal 2025, down 6.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Amarin Corp Plc\Uk returned โ to shareholders in fiscal 2025. The diluted share count rose 1.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Amarin Corp Plc\Uk can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $454M | $309M | $321M | $294M | $303M |
| Debt incl. finance leases | $0.0M | โ | โ | โ | โ |
| Net debt / EBITDA | โ40.9x | โ | โ | โ | โ |
| Debt / equity | 0.0x | โ | โ | โ | โ |
| Interest coverage | 81.4x | โ7,057.9x | โ8,448.5x | โ13,113.9x | โ7,167.1x |
| Current ratio | 2.4x | 2.7x | 2.8x | 3.3x | 3.3x |
| Quick ratio | 1.7x | 1.8x | 1.8x | 2.4x | 2.3x |
| Total assets | $1.1B | $886M | $832M | $685M | $671M |
| Total liabilities | $401M | $291M | $280M | $199M | $211M |
| Shareholders' equity | $667M | $595M | $552M | $486M | $459M |
| Net debt (โ = net cash) | โ$454M | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 4 / 9 | 5 / 9 | 5 / 9 | 4 / 9 | 3 / 9 | 2 / 8 | 4 / 8 | 2 / 8 | 5 / 8 |
| Accruals ratio | โ8.7% | โ21.3% | โ7.9% | โ2.1% | 0.4% | 7.3% | 7.6% | โ7.7% | โ6.7% | โ6.7% |
| Altman Z'' | โ23.45 | โ26.04 | โ9.18 | 1.49 | 0.87 | 0.59 | โ1.09 | โ1.02 | โ2.30 | โ2.07 |
10 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $130M | $181M | $229M | $430M | $614M | $583M | $369M | $307M | $229M | $214M |
| Gross profit | $95.7M | $136M | $175M | $334M | $483M | $462M | $242M | $166M | $81.4M | $121M |
| Research and development | $50.0M | $47.2M | $55.9M | $34.4M | $39.0M | $29.3M | $30.4M | $22.2M | $20.9M | $19.8M |
| Operating income | โ$65.6M | โ$45.6M | โ$108M | โ$24.3M | โ$19.7M | $10.5M | โ$106M | โ$67.6M | โ$91.8M | โ$50.2M |
| Interest expense | $18.7M | $9.8M | $8.9M | $6.6M | $2.6M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Pretax income | โ$76.4M | โ$54.8M | โ$116M | โ$22.5M | โ$17.3M | $11.3M | โ$104M | โ$53.7M | โ$77.2M | โ$36.0M |
| Income tax | $10.0M | $13.0M | $0.1M | $0.2M | $0.7M | $3.6M | $2.0M | $5.4M | $5.0M | $2.8M |
| Net income | โ$86.4M | โ$67.9M | โ$116M | โ$22.6M | โ$18.0M | $7.7M | โ$106M | โ$59.1M | โ$82.2M | โ$38.8M |
| Net income to common | โ$86.4M | โ$67.9M | โ | โ | โ | $7.7M | โ$106M | โ$59.1M | โ$82.2M | โ$38.8M |
| Diluted EPS | โ$0.41 | โ$0.25 | โ$0.39 | โ$0.07 | โ$0.05 | $0.02 | โ$0.26 | โ$0.15 | โ$0.20 | โ$0.09 |
| Diluted shares | 0.21B | 0.27B | 0.30B | 0.34B | 0.38B | 0.40B | 0.40B | 0.41B | 0.41B | 0.41B |
| Cash flow | ||||||||||
| Cash from operations | โ$71.8M | โ$32.8M | โ$94.7M | โ$9.4M | โ$21.7M | โ$66.5M | โ$180M | $6.9M | โ$31.0M | $6.7M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $2.5M | $0.3M | โ | โ | โ | โ | โ |
| Free cash flow | โ$71.8M | โ$32.8M | โ$94.8M | โ$11.8M | โ$22.0M | โ | โ | โ | โ | โ |
| Depreciation and amortization | $0.1M | $0.1M | $0.0M | $0.2M | $0.6M | $0.6M | $0.6M | $0.2M | $0.1M | โ |
| Stock-based compensation | $13.6M | $14.0M | $18.8M | $30.9M | $45.8M | $36.9M | $26.2M | $15.6M | $17.7M | $13.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $98.3M | $73.6M | $249M | $645M | $501M | $454M | $309M | $321M | $294M | $303M |
| Total debt | $93.6M | $92.4M | $79.7M | $49.7M | $0.0M | $0.0M | โ | โ | โ | โ |
| Current assets | $146M | $153M | $378M | $855M | $879M | $879M | $689M | $725M | $595M | $650M |
| Current liabilities | $76.2M | $109M | $157M | $242M | $307M | $371M | $259M | $259M | $180M | $194M |
| Inventory | $20.5M | $30.3M | $57.8M | $76.8M | $189M | $235M | $229M | $259M | $166M | $196M |
| Property and equipment, net | $0.1M | $0.0M | $0.1M | $2.4M | $2.0M | $1.4M | $0.9M | $0.1M | $0.0M | $0.0M |
| Intangible assets | $8.8M | $8.1M | $7.5M | $15.3M | $13.8M | $23.5M | $21.8M | $19.3M | $16.4M | $13.4M |
| Total assets | $167M | $162M | $386M | $882M | $966M | $1.1B | $886M | $832M | $685M | $671M |
| Total liabilities | $176M | $227M | $233M | $274M | $339M | $401M | $291M | $280M | $199M | $211M |
| Preferred stock | $24.4M | $24.4M | $21.9M | $21.9M | โ | โ | โ | โ | โ | โ |
| Shareholders' equity | โ$9.1M | โ$65.1M | $152M | $608M | $628M | $667M | $595M | $552M | $486M | $459M |
| Margins | ||||||||||
| Gross margin | 73.6% | 75.2% | 76.2% | 77.7% | 78.6% | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Operating margin | โ50.4% | โ25.2% | โ47.2% | โ5.6% | โ3.2% | 1.8% | โ28.7% | โ22.0% | โ40.2% | โ23.5% |
| EBITDA margin | โ50.3% | โ25.1% | โ47.2% | โ5.6% | โ3.1% | 1.9% | โ28.5% | โ22.0% | โ40.1% | โ |
| Net margin | โ66.4% | โ37.5% | โ50.8% | โ5.3% | โ2.9% | 1.3% | โ28.7% | โ19.3% | โ35.9% | โ18.2% |
| FCF margin | โ55.2% | โ18.1% | โ41.3% | โ2.8% | โ3.6% | โ | โ | โ | โ | โ |
| Returns | ||||||||||
| Return on capital | โ | โ | โ | โ143.4% | โ12.3% | 3.4% | โ | โ | โ | โ |
| Return on capital employed | โ72.3% | โ85.8% | โ47.4% | โ3.8% | โ3.0% | 1.5% | โ16.9% | โ11.8% | โ18.2% | โ10.5% |
| Return on equity | โ | โ | โ267.0% | โ6.0% | โ2.9% | 1.2% | โ16.8% | โ10.3% | โ15.8% | โ8.2% |
| Return on assets | โ51.7% | โ41.3% | โ42.6% | โ3.6% | โ1.9% | 0.8% | โ10.8% | โ6.9% | โ10.8% | โ5.7% |
| Return on tangible equity | โ | โ | โ80.4% | โ3.8% | โ2.9% | 1.2% | โ18.4% | โ11.1% | โ17.5% | โ8.7% |
| Growth | ||||||||||
| Revenue growth | โ | 39.2% | 26.6% | 87.5% | 42.9% | โ5.0% | โ36.7% | โ16.9% | โ25.5% | โ6.5% |
| Net income growth | โ | โ | โ | โ | โ | โ | โ1,468.9% | โ | โ | โ |
| EPS growth | โ | โ | โ | โ | โ | โ | โ1,400.0% | โ | โ | โ |
| Share count change | โ | 27.7% | 9.8% | 15.2% | 11.5% | 5.4% | โ0.3% | 1.6% | 0.8% | 1.0% |
| Financial health | ||||||||||
| Net debt / EBITDA | โ | โ | โ | โ | โ | โ40.9x | โ | โ | โ | โ |
| Debt / equity | โ | โ | 0.5x | 0.1x | 0.0x | 0.0x | โ | โ | โ | โ |
| Interest coverage | โ3.5x | โ4.7x | โ12.2x | โ3.7x | โ7.5x | 81.4x | โ7,057.9x | โ8,448.5x | โ13,113.9x | โ7,167.1x |
| Current ratio | 1.9x | 1.4x | 2.4x | 3.5x | 2.9x | 2.4x | 2.7x | 2.8x | 3.3x | 3.3x |
| Quick ratio | 1.7x | 1.1x | 2.0x | 3.2x | 2.2x | 1.7x | 1.8x | 1.8x | 2.4x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | โ | โ | โ | โ | โ |
| Stock comp / revenue | 10.5% | 7.7% | 8.2% | 7.2% | 7.5% | 6.3% | 7.1% | 5.1% | 7.7% | 6.5% |
| Quality scores | ||||||||||
| Piotroski F-score | โ | 4.0 | 5.0 | 5.0 | 4.0 | 3.0 | 2.0 | 4.0 | 2.0 | 5.0 |
| Altman Z'' | โ23.4 | โ26.0 | โ9.2 | 1.5 | 0.9 | 0.6 | โ1.1 | โ1.0 | โ2.3 | โ2.1 |
| Accruals ratio | โ8.7% | โ21.3% | โ7.9% | โ2.1% | 0.4% | 7.3% | 7.6% | โ7.7% | โ6.7% | โ6.7% |
Source: SEC EDGAR XBRL filings (CIK 0000897448). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
